Payment overview · 2025
General Payments
$928.37
29 reported records · 20 companies
Healthcare provider profile · identity verified
William Robert Broderick, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · NAPERVILLE, IL · NPI 1164696464
Verified facts
What the public records show
CMS Open Payments records show William Robert Broderick, M.D. received $928.37 in general payments during 2025 across 29 reported records.
Ipsen Biopharmaceuticals, Inc accounted for 15.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Calquence.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Calquence by this doctor in 2024.
BeiGene USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRUKINSA as an associated drug or biological on 2084 records involving 1673 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brukinsa by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Eliquis by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Xarelto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xtandi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $140.00 | 15.1% | 1 | 2025 |
| Menarini Silicon Biosystems, Inc. | Unresolved — no canonical attribution shown | $128.11 | 13.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $67.76 | 7.3% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $55.69 | 6.0% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $54.94 | 5.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.44 | 5.9% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $49.61 | 5.3% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $47.24 | 5.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $45.85 | 4.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.63 | 4.9% | 2 | 2025 |
| Blueprint Medicines Corporation | Unresolved — no canonical attribution shown | $29.71 | 3.2% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $29.23 | 3.1% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $28.41 | 3.1% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $28.29 | 3.0% | 1 | 2025 |
| BeiGene USA, Inc. | Unresolved — no canonical attribution shown | $25.67 | 2.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.00 | 2.6% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $23.86 | 2.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.70 | 2.3% | 1 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $21.37 | 2.3% | 1 | 2025 |
| Orthofix Medical, Inc. | Unresolved — no canonical attribution shown | $6.86 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $928.37 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $140.00 | 1 | 2025 |
Source payment records
|
|||||
| Cellsearch Normalized: cellsearch |
Device | Menarini Silicon Biosystems, Inc. | $128.11 | 1 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $55.69 | 2 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $54.94 | 2 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $49.61 | 2 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $47.24 | 2 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $45.85 | 2 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Drug | Blueprint Medicines Corporation | $29.71 | 1 | 2025 |
Source payment records
|
|||||
| Itovebi Normalized: itovebi |
Biological | Genentech USA, Inc. | $29.23 | 1 | 2025 |
Source payment records
|
|||||
| ZEPZELCA Normalized: zepzelca |
Drug | JAZZ PHARMACEUTICALS INC. | $28.41 | 1 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $28.29 | 1 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $27.26 | 1 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $26.60 | 1 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $26.60 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $26.47 | 1 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeiGene USA, Inc. | $25.67 | 1 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $23.86 | 1 | 2025 |
Source payment records
|
|||||
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| Zoladex Normalized: zoladex |
Drug | TerSera Therapeutics LLC | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $19.03 | 1 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | PFIZER INC. | $19.03 | 1 | 2025 |
Source payment records
|
|||||
| Cervical-Stim Normalized: cervical stim |
Device | Orthofix Medical, Inc. | $6.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CALQUENCE calquence |
2025 | Calquence | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| BeiGene USA, Inc. Exact reporting entity; no affiliate inference |
2025 | BRUKINSA open payments reported associated product |
CMS Open Payments — General Payments 2084 supporting records · 1673 recipient NPIs · example record 1202877750 |
Brukinsa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
167 | 35 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
86 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
167 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 167 | 35 |
| Prednisone | Prednisone | 128 | 28 |
| Warfarin Sodium | Warfarin Sodium | 103 | 22 |
| Xarelto | Rivaroxaban | 86 | 19 |
| Abiraterone Acetate | Abiraterone Acetate | 68 | suppressed |
| Dexamethasone | Dexamethasone | 53 | 18 |
| Hydroxyurea | Hydroxyurea | 47 | suppressed |
| Acyclovir | Acyclovir | 41 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 35 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 15 |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | 12 |
| Calquence | Acalabrutinib Maleate | 19 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 19 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 16 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Xtandi | Enzalutamide | 12 | suppressed |
| Brukinsa | Zanubrutinib | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $928.37 · 29 records | Ipsen Biopharmaceuticals, Inc | AYVAKIT, CALQUENCE, Cellsearch, Cervical-Stim, Enhertu, IBRANCE, INLYTA, Itovebi, KEYTRUDA, KEYTRUDA QLEX, LIBTAYO, Onivyde, PADCEV, PLUVICTO, REBLOZYL, RYBREVANT, SARCLISA, TEVIMBRA, TUKYSA, VERZENIO, ZEPZELCA, Zoladex | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Calquence play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error